Muthanna Medical Journal (Sep 2022)
Complete remission of Hodgkin Lymphoma after a concurrent infection with COVID-19: systematic review and meta-analysis
Abstract
Through December 2019, novel coronavirus (SARS-CoV-2) pneumonia (COVID-19) was reported in Wuhan and has since rapidly spread throughout China. Hodgkin lymphoma represents a heterogeneous hematological malignancy, which is characterized by immunosuppression. There are no clearly defined risk factors for the development of this disease and the cause of remains unknown. Factors shown to be associated with Hodgkin include familial factors, viral exposures, and immune suppression. An electronic search was performed to identify all studies reporting on the management of Hodgkin lymphoma patients during the COVID-19 pandemic. The PubMed/MEDLINE database was searched on October 30th, 2019, to January 30th. 2022. The search strategy was SARS-CoV-2 or COVID-19 and Hodgkin lymphoma. We aimed to clarify the clinical outcome of COVID-19 in patients with Hodgkin lymphoma through systematic review and meta-analysis.
Keywords